Azor Biotek is developing microRNA-targeting small molecule therapeutics. Our lead therapeutics are designed to target miR-29 and miR-223 as multimodal tumor inhibitors. Our design platform leverages high-throughput zebrafish phenotypic, molecular and pharmacokinetic data. We have therapeutic development pipelines in place for glioblastoma as well as neurodegenerative, fibrotic, cardiovascular and psychiatric indications.
| Website | http://azorbiotek.ca |
| Employees | 2 (2 on RocketReach) |
| Founded | 2019 |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Rna Therapeutics, Neurodegenerative Diseases, Small Molecule Drugs, Drug Development, Gene Silencing, Pharmaceutical Research, Molecular Medicine, Biotechnology, Therapeutics, Precision Medicine, Drug Discovery, Innovative Therapies, New Drug Delivery, Biopharma, Life Sciences, Clinical Trials, Rare Diseases |
Looking for a particular Azor Biotek employee's phone or email?
Azor Biotek Questions
Brock Schuman is the CEO of Azor Biotek.
2 people are employed at Azor Biotek.
Top Azor Biotek Employees
-
Brock Schuman
CEO at Azor Biotek
Victoria, BC, CA11 -
53
Related Companies
G2Crowd Trusted
300K+
Plugin Users
